- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00363467
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
A Pilot Study of Intravenous, Targeted-Dose Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation in High-Risk AML
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Pre- Transplantation Phase -
- Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously. Alternatively, patients may receive G-CSF alone (same dose) as mobilization therapy.
- Leukapheresis will begin day 4 of G-CSF administration and proceed according to institutional guidelines. Leukapheresis will continue until a target goal for recipient body weight is obtained, or up to a maximum of 5 days. A minimum recipient body weight is required to proceed to transplantation.
Transplantation Phase
a. Conditioning/Preparative therapy - up to 30 days following PBSC collection, patients will begin conditioning therapy with Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2; subsequent doses will be adjusted based on pharmacokinetic monitoring.
- Busulfan plasma level monitoring, collected around the first dose of busulfan b. Stem cell reinfusion - following 1 day of rest, previously collected autologous peripheral blood stem cells will be infused.
- The administration of supportive measures (e.g. intravenous fluids, antihistamines) during stem cell reinfusion will be performed according to institutional guidelines.
Supportive care
- Antibiotic prophylaxis- according to hospital/institutional guidelines, and at the discretion of the treating physician.
- Growth factor support
- Transfusion support
- Prophylaxis for busulfan-induced seizures
During follow-up, patients will be seen at least weekly for the first month and there after periodically out to 730 days posttransplant. The following medical procedures will be done:
- Medical history and physical exam (including concurrent meds, vital signs, performance status and weight)
- Standard labs
- Bone marrow aspirate and biopsy
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients must have had histologically confirmed diagnosis of AML, in 1st complete remission, by a pathologic review at the H. Lee Moffitt Cancer Center and Research Institute. Any induction/consolidation regimen is permitted.
General Inclusion Criteria:
- Age 56-74
- Able to give informed consent
- Hepatic and renal function: normal bilirubin, AST and ALT less than or equal to 2x normal limits, serum creatinine less than or equal to 1.5x normal
- Left ventricular ejection fraction (LVEF) must be in normal range
- FEV1 AND DLCO greater than or equal to 50% predicted (at planned time of transplantation)
- ECOG PS less than or equal to 2 (at planned time of transplantation)
Disease Specific Inclusion Criteria:
- Adverse-risk karyotype (del 5/5q, 7/7q, 3q, greater than or equal to 3 abnormalities):
- Intermediate-risk karyotype [46 XY, +8, -Y, +6, or any other isolated (<3 total) non-random abnormality not included in the adverse-risk category or favorable-risk category below]
- AML arising from antecedent hematologic disorder (e.g. MDS)
- Secondary AML (t-AML)
Exclusion Criteria:
- Acute Promyelocytic Leukemia(FAB M3) subtype
- Presence of (8;21) translocation or inversion 16/t(16;16) cytogenetic phenotype (i.e. favorable-risk AML)
- Eligible for and willing to undergo matched-sibling allogeneic transplantation
- Greater than 2 induction regimens required to achieve complete remission
- Duration of > 8 weeks between completion of induction chemotherapy and initiation of consolidation chemotherapy
- No prior malignancy is allowed, except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 5 years.
- Prior extensive radiation therapy (>25% of bone marrow reserve)
- Concomitant radiation therapy, chemotherapy, or immunotherapy
- Intrinsic impaired organ function (as stated above)
- Active infection
- Positive serum pregnancy test in women who have not yet reached menopause (no menstrual periods for >12 months or who have not undergone tubal ligation or complete hysterectomy.
- Women who are breast-feeding
- Positive HIV testing
- Presence of CNS leukemia
- Uncontrolled insulin-dependent diabetes mellitus or uncompensated major thyroid or adrenal gland dysfunction
- Physical or psychiatric conditions that in the estimation of the PI or his designee place the patient at high-risk of toxicity or non-compliance
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Otro: Autologous Hematopoietic Progenitor Cell Transplantation
G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion
|
Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously. Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously.
Otros nombres:
leukapheresis
Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2).
The day -5 and -4 dose will be 130mg/m2
Otros nombres:
autologous stem cell transplant
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
100-day Non-relapse Mortality
Periodo de tiempo: 100 days post transplant
|
100-day non-relapse mortality is the number of participants who died before day 100 posttransplant from causes other than relapsed disease
|
100 days post transplant
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Successful Autologous Stem Cell Collection
Periodo de tiempo: At time of stem cell collection
|
Number of subjects who were able to collect at least 2 million CD34+ cells/kg
|
At time of stem cell collection
|
Severe Regimen-related Toxicity
Periodo de tiempo: up to 100 days post translant
|
Number of participants with severe regimen-related toxicity within 2 years posttransplant.
Severe regimen-related toxicity was defined as CTC (version 3)grade 4.
|
up to 100 days post translant
|
1 Year Event-free Survival
Periodo de tiempo: 1 year post transplant
|
Number of participants alive and without disease relapse at 1 year posttransplant
|
1 year post transplant
|
1 Year Overall Survival
Periodo de tiempo: 1 year post transplant
|
Number of participants alive at 1 year posttransplant
|
1 year post transplant
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jeffrey E Lancet, MD, H. Lee Moffitt Cancer Center and Research Institute
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Leucemia
- Leucemia Mieloide
- Leucemia Mieloide Aguda
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Agentes antineoplásicos, alquilantes
- Agentes alquilantes
- Agonistas mieloablativos
- Busulfán
Otros números de identificación del estudio
- MCC-14604
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre G-CSF
-
Zhongnan HospitalAún no reclutandoFactor estimulante de colonias de granulocitosPorcelana
-
Sun Yat-sen UniversityReclutamientoInhibidor de PD-1 | G-CSFPorcelana
-
Institute of Liver and Biliary Sciences, IndiaTerminadoHepatitis Alcohólica SeveraIndia
-
National Heart, Lung, and Blood Institute (NHLBI)TerminadoAnemia de Diamond BlackfanEstados Unidos
-
National Heart, Lung, and Blood Institute (NHLBI)TerminadoAnemia aplásicaEstados Unidos
-
Axaron Bioscience AGTerminado
-
Centre for Endocrinology and Reproductive Medicine...DesconocidoEsterilidad | Desarrollo embrionario | FIVItalia
-
GPCR Therapeutics, Inc.TerminadoMieloma múltiple | Enfermedad de Hodgkin | No linfoma de HodgkinEstados Unidos
-
Xinhua Hospital, Shanghai Jiao Tong University...DesconocidoLinfoma | Leucemia mieloide aguda | Neuroblastoma | Retinoblastoma | Hepatoblastoma | Leucemia linfoide agudaPorcelana